Welcome to our dedicated page for Erasca news (Ticker: ERAS), a resource for investors and traders seeking the latest updates and insights on Erasca stock.
Erasca, Inc. (ERAS) is a clinical-stage precision oncology company pioneering therapies for cancers driven by RAS/MAPK pathway abnormalities. This page serves as the definitive source for official updates spanning clinical developments, regulatory milestones, and strategic initiatives.
Investors and researchers will find curated news about Erasca’s pipeline candidates including pan-RAF inhibitor naporafenib, ERK1/2 inhibitor ERAS-007, and emerging preclinical assets. Our repository includes trial progress reports, partnership announcements, and scientific presentations – all essential for tracking advancements in targeted cancer therapies.
Regular updates cover key areas: clinical trial phase transitions, FDA designations, collaborative research agreements, and preclinical discoveries. Each release is vetted for accuracy, providing reliable insights into Erasca’s mission to disrupt oncogenic signaling pathways.
Bookmark this page for streamlined access to ERAS news. Combine our updates with SEC filings and scientific publications for comprehensive analysis of this innovative oncology biotech.
Erasca has announced the in-licensing of two preclinical RAS programs: ERAS-0015, a pan-RAS molecular glue, and ERAS-4001, a pan-KRAS inhibitor. Both compounds show high potency and oral bioavailability, with the potential to address unmet needs in RAS-mutant tumors. Concurrently, Erasca has priced a $160 million equity offering.
In connection with these new programs, Erasca will deprioritize several existing projects and restructure its workforce, impacting 18% of employees. The company aims to focus on programs with the highest success probabilities. Key upcoming milestones for the pipeline include Phase 1 and Phase 3 trials for various compounds, with initial data expected in late 2024 and beyond.
Erasca, a clinical-stage precision oncology company focused on RAS/MAPK pathway-driven cancers, announced the pricing of an underwritten offering of 86,486,486 shares of its common stock at $1.85 per share.
The offering is expected to raise approximately $160 million before underwriting discounts and expenses. Erasca has also granted underwriters a 30-day option to purchase an additional 12,972,972 shares.
The offering is anticipated to close on May 21, 2024, subject to customary closing conditions. J.P. Morgan and BofA Securities are the joint book-running managers.
Proceeds will fund research and development, as well as general corporate purposes. The offering is made under a shelf registration statement effective August 18, 2022.
Erasca, Inc. (Nasdaq: ERAS) reported strong Q1 2024 results with promising survival data for naporafenib plus trametinib in patients with NRASm melanoma, leading to an oversubscribed $45 million financing. The company extended its cash runway into H2 2026 and expects upcoming data readouts across multiple clinical programs. R&D and corporate highlights showcase continued progress and collaborations, positioning Erasca well for future growth.
Erasca, Inc. (Nasdaq: ERAS) will be presenting at the Bank of America Health Care Conference in Las Vegas, Nevada. The company focuses on developing therapies for RAS/MAPK pathway-driven cancers. The presentation will take place on May 15, 2024, at 4:20 pm Pacific Time.
FAQ
What is the current stock price of Erasca (ERAS)?
What is the market cap of Erasca (ERAS)?
